

Erratum: Daclatasvir plus sofosbuvir, with or without ribavirin, achieved high sustained virological response rates in patients with HCV infection and advanced liver disease in a real-world cohort

Welzel TM, Petersen J, Herzer K, *et al.* Daclatasvir plus sofosbuvir, with or without ribavirin, achieved high sustained virological response rates in patients with HCV infection and advanced liver disease in a real-world cohort. *Gut* 2016;65:1861–70. The trial registration number has been corrected to NCT02097966.

Gut 2016;65:2060. doi:10.1136/gutjnl-2016-312444corr1

